Licenses radiation-controlled in vivo gene therapy technology from the University of Chicago and Dana Farber Cancer Institute, company announces Nov. 29. The therapeutic genetic therapy, which could be delivered to specific organs via traditional pharmaceutical formulations, can be switched on by radiation at the time and level desired to produce toxins that kill cancer cells. The primary inventors of the technology, Ralph Weichselbaum, MD, University of Chicago, and Dana Farber's Donald Kufe, MD, will become Founding Scientific Advisors of GenVec.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth